Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351999 | 0.92 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL2351267 | 0.92 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL2348407 | 0.91 | PTGS2 (0.57) | PTGS2PTGS1PGR | |
| SCHEMBL2353756 | 0.89 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL2351484 | 0.89 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL2320143 | 0.87 | PTGS2 (0.52) | PTGS2PTGS1NR3C1PGRNR3C2 | |
| SCHEMBL3337047 | 0.86 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL2349594 | 0.86 | PTGS2 (0.58) | PTGS2PTGS1NR3C1PGRNR3C2 | |
| SCHEMBL2349582 | 0.83 | PTGS2 (0.49) | PTGS2PTGS1PGR | |
| SCHEMBL1961471 | 0.83 | PTGS2 (0.47) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1767529-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1767529-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, CYP4Z1 | PTGS2 630/4885PTGS1 370/4885NR3C1 1093/4885 |
| US-20090281337-A1 | Pyridazine compound and use thereof | PLPBP, PNPO, CYP4Z1 | PTGS2 630/4885PTGS1 370/4885NR3C1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.